Clinical trials: Pandemic Influenza, open to volunteers
Respiratory Tract Diseases, Influenza (Pandemic)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised…
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
Influenza (Healthy Volunteers)
Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness
The overall objective is to establish an influenza Controlled Human Infection Model (CHIM) in Canada that can be used to assess the safety and efficacy of candidate vaccines, biologics, and therapeutics targeting influenza…
- Trial name
- NCT07305207
- Testing
- Intranasal inoculation of RG-A/Texas/71/2017 (H3N2) influenza in each naris on Day 1 of the study.
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Dalhousie University
Influenza Prevention, Pandemic Influenza Prevention
Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults
Background: Influenza (flu) is a contagious respiratory illness caused by viruses. Flu symptoms can range from mild to severe, and the illness can be fatal. Vaccines help the body learn to prevent or fight infections such as flu.
- Trial name
- NCT07111078
- Testing
- VRC-FLUMOS0122-00-VP, ALFQ
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Infections, COVID-19
Volatile Organic Compounds Analysis by GC-MS for Diagnostic of Hospitalised Patients With Respiratory Infections Using Exhaled Breath
Emerging respiratory diseases represent a global threat. Viruses such as influenza and coronaviruses have been the main drivers of pandemics over the past century.
- Conditions
- Respiratory Infections, COVID-19, Influenza Virus Infection, Legionella Pneumophila Infections
- Trial name
- VORTEX-2 (NCT07352462)
- Testing
- Volatile Organic compounds (VOC) analysis in Exhaled breath using GC-MS
- Where
- 7 sites in France
- Volunteers
- 777 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
covid19 Infection, Influenza, Human
Covid-19 and Influenza Oral Vaccine Study
The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral/ sublingual mucosal route instead of intramuscular delivery.
- Trial name
- NCT06355232
- Testing
- Covid-19 vaccine, Influenza vaccine
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd